What is Leerink Partnrs’ Forecast for DNLI FY2025 Earnings?

Denali Therapeutics Inc. (NASDAQ:DNLI) – Research analysts at Leerink Partnrs lowered their FY2025 earnings estimates for Denali Therapeutics in a report released on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($3.45) per share for the year, down from their prior estimate of ($2.80). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.73) per share. Leerink Partnrs also issued estimates for Denali Therapeutics’ FY2026 earnings at ($2.40) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at ($0.55) EPS.

A number of other brokerages have also issued reports on DNLI. Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. William Blair reiterated an “outperform” rating on shares of Denali Therapeutics in a research report on Wednesday, January 15th. Robert W. Baird started coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price target for the company. Jefferies Financial Group lifted their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Finally, The Goldman Sachs Group reduced their target price on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Denali Therapeutics Trading Down 1.2 %

Shares of DNLI opened at $23.30 on Friday. The firm has a market cap of $3.35 billion, a P/E ratio of -8.44 and a beta of 1.39. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $33.33. The stock’s 50 day moving average is $22.42 and its two-hundred day moving average is $24.83.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the previous year, the business posted ($0.72) earnings per share.

Insider Buying and Selling

In other news, CEO Ryan J. Watts sold 29,266 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the sale, the chief executive officer now owns 260,721 shares in the company, valued at $5,271,778.62. This trade represents a 10.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Vicki L. Sato sold 1,020 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the completion of the transaction, the director now owns 111,056 shares in the company, valued at $3,331,680. This represents a 0.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 64,518 shares of company stock worth $1,469,382. Insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Victory Capital Management Inc. boosted its stake in Denali Therapeutics by 163.7% during the third quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock worth $1,162,000 after buying an additional 24,767 shares during the period. FMR LLC boosted its position in shares of Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after purchasing an additional 7,596,508 shares during the period. Algert Global LLC boosted its position in shares of Denali Therapeutics by 82.4% during the 3rd quarter. Algert Global LLC now owns 48,630 shares of the company’s stock worth $1,417,000 after purchasing an additional 21,975 shares during the period. JPMorgan Chase & Co. increased its holdings in Denali Therapeutics by 6.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock valued at $6,857,000 after purchasing an additional 14,324 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after purchasing an additional 149,939 shares in the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.